Pharmacokinetics of amiodarone: implications for drug therapy.

[1]  V. Backer,et al.  Serial pulmonary function tests in patients treated with low-dose amiodarone. , 1992, American heart journal.

[2]  M. D. Freedman,et al.  Pharmacology and Pharmacokinetics of Amiodarone , 1991, Journal of clinical pharmacology.

[3]  D. Roden,et al.  Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. , 1991, Circulation research.

[4]  A. Kadish,et al.  Magnitude and time course of beta-adrenergic antagonism during oral amiodarone therapy. , 1990, Journal of the American College of Cardiology.

[5]  E. Giardina,et al.  Myocardial amiodarone and desethylamiodarone concentrations in patients undergoing cardiac transplantation. , 1990, Journal of the American College of Cardiology.

[6]  J J Heger,et al.  Clinical features of amiodarone-induced pulmonary toxicity. , 1990, Circulation.

[7]  P. Laurberg,et al.  Rat Heart Thyroxine 5'-Deiodinase is Sensitively Depressed by Amiodarone , 1989, Journal of cardiovascular pharmacology.

[8]  S. Carruthers,et al.  Correlation of amiodarone dosage, heart rate, QT interval and corneal microdeposits with serum amiodarone and desethylamiodarone concentrations. , 1989, The American journal of cardiology.

[9]  D. Wyse,et al.  Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects. , 1989, Circulation.

[10]  T. Guarnieri,et al.  Serial lung function testing in patients treated with amiodarone: a prospective study. , 1989, The American journal of medicine.

[11]  J. Mason.  Prediction of amiodarone-induced pulmonary toxicity. , 1989, The American journal of medicine.

[12]  S. Connolly,et al.  Concentration response relationships of amiodarone and desethylamiodarone. , 1988, American heart journal.

[13]  D. Roden,et al.  The development and testing of intravenous dosing regimens: Application to flecainide for the suppression of ventricular arrhythmias , 1988, Clinical pharmacology and therapeutics.

[14]  A. Katz,et al.  Possible molecular basis for the pharmacokinetics and pharmacodynamics of three membrane-active drugs: propranolol, nimodipine and amiodarone. , 1988, Journal of molecular and cellular cardiology.

[15]  S. Nattel,et al.  The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction. , 1988, Circulation.

[16]  B. Lerman,et al.  Predictors of efficacy of amiodarone and characteristics of recurrence of arrhythmia in patients with sustained ventricular tachycardia and coronary artery disease. , 1987, Circulation.

[17]  M. Josephson,et al.  Relationship of steady-state serum concentrations of amiodarone and desethylamiodarone to therapeutic efficacy and adverse effects. , 1987, The American journal of medicine.

[18]  Mark L. Greenberg,et al.  Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity. , 1987, Journal of the American College of Cardiology.

[19]  R. Goldstein,et al.  Interaction of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors. , 1987, Journal of the American College of Cardiology.

[20]  S. Swillens,et al.  Allosteric Modulation of [3H]Nitrendipine Binding to Cardiac and Cerebral Cortex Membranes by Amiodarone , 1986, Journal of cardiovascular pharmacology.

[21]  P. Zampieri,et al.  Amiodarone and desethylamiodarone distribution in the atrium and adipose tissue of patients undergoing short- and long-term treatment with amiodarone. , 1986, Journal of the American College of Cardiology.

[22]  D. Tepper,et al.  QT prolongation and the antiarrhythmic efficacy of amiodarone. , 1986, Journal of the American College of Cardiology.

[23]  P. Chatelain,et al.  Amiodarone partitioning with phospholipid bilayers and erythrocyte membranes. , 1985, Journal of pharmaceutical sciences.

[24]  S. Yabek,et al.  Acute effects of amiodarone on the electrophysiologic properties of isolated neonatal and adult cardiac fibers. , 1985, Journal of the American College of Cardiology.

[25]  R. Bruno,et al.  Amiodarone and desethylamiodarone elimination kinetics following withdrawal of long-term amiodarone maintenance therapy. , 1985, Biopharmaceutics & drug disposition.

[26]  J. Desager,et al.  Absolute bioavailability of amiodarone in normal subjects , 1985, Clinical pharmacology and therapeutics.

[27]  L. Horowitz,et al.  Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. , 1984, Annals of internal medicine.

[28]  B. Singh,et al.  Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue drug concentrations. , 1984, American heart journal.

[29]  N. Mostow,et al.  Amiodarone: correlation of serum concentration with suppression of complex ventricular ectopic activity. , 1984, The American journal of cardiology.

[30]  S. Saksena,et al.  Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia. , 1984, The American journal of cardiology.

[31]  M. Lalloz,et al.  Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands , 1984, The Journal of pharmacy and pharmacology.

[32]  E. Prystowsky,et al.  Plasma and red blood cell concentrations of amiodarone during chronic therapy. , 1984, The American journal of cardiology.

[33]  A. Camm,et al.  The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. , 1984, British heart journal.

[34]  D. Roden,et al.  Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. , 1984, The Journal of clinical investigation.

[35]  J. Alpert,et al.  Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: dosage experience. , 1983, American heart journal.

[36]  N. Mostow,et al.  Amiodarone pulmonary toxicity. , 1983, American heart journal.

[37]  P. Adams,et al.  High-performance liquid chromatographic measurement of amiodarone and desethylamiodarone in small tissue samples after enzymatic digestion. , 1983, Journal of clinical pathology.

[38]  W. Mckenna,et al.  Renal elimination of amiodarone and its desethyl metabolite. , 1983, Postgraduate medical journal.

[39]  J. Alpert,et al.  Clinical Pharmacokinetics and Efficacy of Amiodarone for Refractory Tachyarrhythmias , 1983, Circulation.

[40]  J. Derancourt,et al.  Determination of cardiac and plasma drug levels during long‐term amiodarone therapy , 1983, European journal of clinical investigation.

[41]  L. Lesko,et al.  Amiodarone for Tachyarrhythmias: Pharmacology, Kinetics, and Efficacy , 1983, Drug intelligence & clinical pharmacy.

[42]  P. Curry,et al.  High‐Performance Liquid Chromatographic Measurement of Amiodarone and Its Desethyl Metabolite: Methodology and Preliminary Observations , 1982, Therapeutic drug monitoring.

[43]  M. Anastasiou-Nana,et al.  Pharmacokinetics of amiodarone after intravenous and oral administration. , 1982, International journal of clinical pharmacology, therapy, and toxicology.

[44]  P. Farmer,et al.  Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone‐treated patients , 1982, The Journal of pharmacy and pharmacology.

[45]  D. Holt,et al.  High-performance liquid chromatographic measurement of amiodarone and desethylamiodarone in plasma or serum at the concentrations attained following a single 400-mg dose. , 1982, Journal of chromatography.

[46]  K. Nademanee,et al.  Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia. , 1982, American heart journal.

[47]  K. Nademanee,et al.  Amiodarone kinetics after oral doses , 1982, Clinical pharmacology and therapeutics.

[48]  E. Riva,et al.  Pharmacokinetics of Amiodarone in Rats , 1982, Journal of cardiovascular pharmacology.

[49]  L. Sheiner,et al.  The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships. , 1981, British Journal of Clinical Pharmacology.

[50]  F. Harrell,et al.  Procainamide delivery to ischemic canine myocardium following rapid intravenous administration. , 1980, Circulation research.

[51]  B. Katzung,et al.  Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. , 1977, Biochimica et biophysica acta.

[52]  P. Polster,et al.  The adrenergic antagonism of amiodarone. , 1976, Biochemical pharmacology.

[53]  G. Strichartz,et al.  The Inhibition of Sodium Currents in Myelinated Nerve by Quaternary Derivatives of Lidocaine , 1973, The Journal of general physiology.

[54]  J. Broekhuysen,et al.  Recherches dans la série des benzofurannes. XXXVII. Etude comparée du transit et du métabolisme de l'amiodarone chez diverses espèces animales et chez l'homme. , 1969 .